Deutsch English Français

Contact

EP2303337

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2303337

EP2303337 - SMALL MOLECULE LIGAND-DRUG CONJUGATES FOR TARGETED CANCER THERAPY [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 24.11.2017 Database last updated on 17.09.2024
Former	Examination is in progress Status updated on 25.03.2017
Most recent event Tooltip	24.11.2017	Application deemed to be withdrawn	published on 27.12.2017 [2017/52]
Applicant(s)	For all designated states Cedars-Sinai Medical Center 8700 Beverly Boulevard Los Angeles, CA 90048 / US
	For all designated states Emory University 1380 S. Oxford Road Atlanta, GA 30322 / US
	[N/P]
Former [2011/14]	For all designated states Cedars-Sinai Medical Center 8700 Beverly Boulevard Los Angeles, California 90048 / US
	For all designated states Emory University 1380 S. Oxford Road Atlanta, GA 30322 / US
Inventor(s)	01 / CHUNG, Leland, W., K. 1136 Clifton Road Atlanta GA 30307 / US
	02 / YANG, Xiaojian 61 Building, 59 15 Changle West Road Xi'an, Shaanxi 710032 / CN
	03 / CHENG, Jianjun 2304 Lynwood Drive Champaign IL 61821 / US
	04 / TONG, Rong 100 Memorial Drive Apartment 8-20B Cambridge MA / US
	[2011/33]
Former [2011/14]	01 / CHUNG, Leland, W., K. 1136 Clifton Road Atlanta GA 30307 / US
	02 / YANG, Xiaojian 5285 Village View Lane Stone Mountain GA 30087 / US
	03 / CHENG, Jianjun 2304 Lynwood Drive Champaign IL 61821 / US
	04 / TONG, Rong 510 East Michigan Avenue Urbana IL 61801 / US
Representative(s)	HGF 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB
	[N/P]
Former [2014/07]	Holmes, Michael Anthony, et al Harrison Goddard Foote LLP 4th Floor, Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB
Former [2011/14]	Harrison Goddard Foote 4th Floor, Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB
Application number, filing date	09763728.4	12.06.2009
	[2011/14]
	WO2009US47216
Priority number, date	US20080061346P	13.06.2008 Original published format: US 61346 P
	[2011/14]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2009152440
	Date:	17.12.2009
	Language:	EN
	[2009/51]
	Type:	A1 Application with search report
	No.:	EP2303337
	Date:	06.04.2011
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 17.12.2009 takes the place of the publication of the European patent application.
	[2011/14]
Search report(s)	International search report - published on:	US	17.12.2009
	(Supplementary) European search report - dispatched on:	EP	01.08.2014
Classification	IPC:	A61K51/00, A61M36/14, A61K47/48	[2014/35]
	CPC:	A61K49/0002 (EP,US); A61K47/545 (EP,US); A61K47/546 (EP,US); A61K49/0032 (EP,US); A61K49/0052 (EP,US); A61P35/00 (EP)
	Former IPC [2011/14]	A61K51/00, A61M36/14
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2011/14]
Title	German:	KLEINMOLEKÜLIGE LIGANDEN-ARZNEIMITTEL-KONJUGATE FÜR DIE GEZIELTE KREBSTHERAPIE	[2011/14]
	English:	SMALL MOLECULE LIGAND-DRUG CONJUGATES FOR TARGETED CANCER THERAPY	[2011/14]
	French:	CONJUGUÉS MÉDICAMENT-LIGAND À PETITE MOLÉCULE POUR TRAITEMENT CIBLÉ CONTRE LE CANCER	[2011/14]
Entry into regional phase	13.01.2011	National basic fee paid
	13.01.2011	Search fee paid
	13.01.2011	Designation fee(s) paid
	13.01.2011	Examination fee paid
Examination procedure	13.01.2011	Examination requested [2011/14]
	02.03.2015	Amendment by applicant (claims and/or description)
	24.11.2015	Despatch of a communication from the examining division (Time limit: M06)
	13.09.2016	Reply to a communication from the examining division
	15.03.2017	Despatch of a communication from the examining division (Time limit: M04)
	26.07.2017	Application deemed to be withdrawn, date of legal effect [2017/52]
	23.08.2017	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2017/52]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 24.11.2015
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	13.09.2016	Request for further processing filed
	13.09.2016	Full payment received (date of receipt of payment) Request granted
	27.09.2016	Decision despatched
Fees paid	Renewal fee
	27.06.2011	Renewal fee patent year 03
	25.07.2012	Renewal fee patent year 04
	19.08.2013	Renewal fee patent year 05
	12.06.2014	Renewal fee patent year 06
	29.06.2015	Renewal fee patent year 07
	27.06.2016	Renewal fee patent year 08
	27.06.2017	Renewal fee patent year 09
	Penalty fee
	Additional fee for renewal fee
	30.06.2012	04 M06 Fee paid on 25.07.2012
	30.06.2013	05 M06 Fee paid on 19.08.2013
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO0238190 (BETH ISRAEL HOSPITAL [US], et al) [X] 1-17 * Conjugates of pamidonate (a drug) and an indol-polyene molecule carrying a side chain portion, separated by a spacer. *;
		[X]WO03032901 (MALLINCKRODT INC [US], et al) [X] 1-17 * Conjugates comprising a cyanidin moiety as defined in the claims, octreotide or octreotate (i.e. a drug) and possibly also a phorbate moiety i.e. a label: see claims, figure 1 and examples 4-8 *;
		[X]WO03055935 (UNIV TEXAS [US]) [X] 1-17 * Cyanin derivatives as defined in claims, conjugated by a spacer to folic acid, i.e. a drug (See figure 13 and example 9, on page 69). Other drugs, including paclitaxel can be included in the conjugate: see pages 29-31, claim 44. *;
		[Y]EP1679082 (SCHERING AG [DE]) [Y] 1-17 * Cyanine compound for imaging, which is readily uptaken in tumoral tissues: see claims and paragraphs 11, 13, 42 *;
		[Y] - SUN X ET AL, "Anticarcinoma activity of a novel drug, 3-ethyl-3'-methyl- thiatelluracarbocyanine iodide (Te), a tellurium-containing cyanine targeted at mitochondria", CLINICAL CANCER RESEARCH 199608 US, (199608), vol. 2, no. 8, ISSN 1078-0432, pages 1335 - 1340, XP002727407 [Y] 1-17 * See abstract and results: cyanine dyes accumulate in the mithochondria of carcinoma cells *
		[T] - ZHANG ERLONG ET AL, "Mechanistic study of IR-780 dye as a potential tumor targeting and drug delivery agent.", BIOMATERIALS JAN 2014, (201401), vol. 35, no. 2, ISSN 1878-5905, pages 771 - 778, XP002727408 [T] * See abstract and page 777: IR-780, as drug targeting and drug delivery agent * DOI: http://dx.doi.org/10.1016/j.biomaterials.2013.10.033
		[T] - XIAO LI ET AL, "Heptamethine cyanine based (64)Cu-PET probe PC-1001 for cancer imaging: synthesis and in vivo evaluation.", NUCLEAR MEDICINE AND BIOLOGY APR 2013, (201304), vol. 40, no. 3, ISSN 1872-9614, pages 351 - 360, XP002727409 [T] * See abstract and passage bridging left and right hand column on page 359: small molecules as delivery agents * DOI: http://dx.doi.org/10.1016/j.nucmedbio.2013.01.001
	International search	[Y]US6191290 (SAFAVY AHMAD [US]);
		[Y]US6214812 (KARPEISKY MARAT [US], et al);
		[Y]US2004052727 (DALTON JAMES T [US], et al);
		[Y]US2005255042 (LAM KIT S [US], et al);
		[X]US2005281741 (ACHILEFU SAMUEL I [US], et al);
		[Y]US2006292078 (KLAVENESS JO [NO], et al);
		[A]US2007140962 (ACHILEFU SAMUEL [US], et al)
	Examination	- SONG Y ET AL, "Conjugate of mitomycin C with N-succinyl-chitosan: In vitro drug release properties, toxicity and antitumor activity", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 98, no. 1-3, doi:10.1016/0378-5173(93)90048-K, ISSN 0378-5173, (19930831), pages 121 - 130, (19930831), XP025565447 DOI: http://dx.doi.org/10.1016/0378-5173(93)90048-K

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p